Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.
Eur J Clin Invest. 2011 Apr;41(4):405-10. doi: 10.1111/j.1365-2362.2010.02422.x. Epub 2011 Jan 17.
Given that role of magnesium in insulin secretion is uncertain, our objective was to determine whether oral supplementation with magnesium chloride (MgCl(2)) improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia.
Eligible individuals were non-diabetic, normo-tensive men and non-diabetic, normo-tensive, non-pregnant women with serum magnesium levels ≤0·70 mM/L; they were enrolled in a randomized double-blind clinical trial to receive either 50 mL of 5% MgCl(2) solution or 50 mL of inactive solution daily for 3 months. The primary trial end point was a change in the AUC of the hyperbolic model of beta-cell function (HMbCF) derived from the fasting state. Individuals, caregivers and personnel who assessed the outcomes were all blinded to the group assignments.
A total of 54 and 52 individuals were assigned to the MgCl(2) and placebo groups, respectively; five individuals in the MgCl(2) group and four in the placebo group dropped out. There were no serious adverse events or side effects because of MgCl(2) or placebo. At the beginning of the study, the AUC of the HMbCF was similar in both groups (AUC = 7·591 and 7·895 cm(2)); at the end of follow-up, the curve of the MgCl(2) group showed a hyperbolic distribution (AUC = 18·855 cm(2)), whereas in the placebo group, there were no changes (AUC = 7·631 cm(2)).
MgCl(2) 2·5 g daily improves the ability of beta-cells to compensate for variations in insulin sensitivity in non-diabetic individuals with significant hypomagnesaemia.
鉴于镁在胰岛素分泌中的作用尚不确定，我们的目的是确定在伴有严重低镁血症的非糖尿病个体中，口服补充氯化镁（MgCl₂）是否能提高β细胞补偿胰岛素敏感性变化的能力。
合格的个体为非糖尿病、血压正常的男性和非糖尿病、血压正常、非妊娠女性，血清镁水平≤0.70 mM/L；他们被纳入一项随机、双盲临床试验，每天接受 50 mL 5% MgCl₂溶液或 50 mL 安慰剂溶液，持续 3 个月。主要试验终点是空腹状态下β细胞功能双曲线模型（HMbCF）的 AUC 变化。个体、护理人员和评估结果的人员均对分组情况不知情。
共有 54 名和 52 名个体分别被分配到 MgCl₂组和安慰剂组，MgCl₂组有 5 名个体和安慰剂组有 4 名个体退出。没有因 MgCl₂或安慰剂而出现严重不良事件或副作用。在研究开始时，两组的 HMbCF AUC 相似（AUC = 7.591 和 7.895 cm²）；随访结束时，MgCl₂组的曲线呈双曲线分布（AUC = 18.855 cm²），而安慰剂组则没有变化（AUC = 7.631 cm²）。
每天 2.5 g MgCl₂可改善伴有严重低镁血症的非糖尿病个体中β细胞补偿胰岛素敏感性变化的能力。
